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Abstract
Background: Early diagnosis of dengue can assist patient triage and management and prevent unnecessary treatments and
interventions. Commercially available assays that detect the dengue virus protein NS1 in the plasma/serum of patients
offers the possibility of early and rapid diagnosis.
Methodology/Principal Findings: The sensitivity and specificity of the Pan-E Dengue Early ELISA and the Platelia
TM Dengue
NS1 Ag assays were compared against a reference diagnosis in 1385 patients in 6 countries in Asia and the Americas. Platelia
was more sensitive (66%) than Pan-E (52%) in confirmed dengue cases. Sensitivity varied by geographic region, with both
assays generally being more sensitive in patients from SE Asia than the Americas. Both kits were more sensitive for
specimens collected within the first few days of illness onset relative to later time points. Pan-E and Platelia were both 100%
specific in febrile patients without evidence of acute dengue. In patients with other confirmed diagnoses and healthy blood
donors, Platelia was more specific (100%) than Pan-E (90%). For Platelia, when either the NS1 test or the IgM test on the
acute sample was positive, the sensitivity versus the reference result was 82% in samples collected in the first four days of
fever. NS1 sensitivity was not associated to disease severity (DF or DHF) in the Platelia test, whereas a trend for higher
sensitivity in DHF cases was seen in the Pan-E test (however combined with lower overall sensitivity).
Conclusions/Significance: Collectively, this multi-country study suggests that the best performing NS1 assay (Platelia) had
moderate sensitivity (median 64%, range 34–76%) and high specificity (100%) for the diagnosis of dengue. The poor
sensitivity of the evaluated assays in some geographical regions suggests further assessments are needed. The combination
of NS1 and IgM detection in samples collected in the first few days of fever increased the overall dengue diagnostic
sensitivity.
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Introduction
Dengue is the most important mosquito-borne viral disease of
humans and an enormous public health burden in affected
countries. An estimated 50–100 million dengue cases occur
annually, including 250,000–500,000 cases of severe illness and
around 25,000 deaths. Approximately 2.5 billion people live in
dengue endemic countries and the illness is reported in Southeast
Asia, Western Pacific, the Americas, Africa and Mediterranean
regions [1–3].
Dengueviruses(DENVs), ofwhichtherearefour serotypes, cause
a variable spectrum of disease that ranges from an undifferentiated
fever to dengue fever (DF) through to more severe syndromes called
dengue haemorrhagic fever (DHF) and dengue shock syndrome
(DSS). DHF/DSS is a vasculopathy characterized by capillary
leakage and haematological dysregulation. There are no licensed
vaccines or specific antiviral therapies for dengue, and patient
management relies on good supportive care.
Early, sensitive and specific diagnosis of dengue can assist in
patient triage and for those who require it, early supportive
www.plosntds.org 1 August 2010 | Volume 4 | Issue 8 | e811management. In principle, early diagnosis could also facilitate
timely public health interventions, e.g. vector control targeted at
the households of index cases. Existing approaches to dengue
diagnosis rely primarily on detection of DENV-reactive IgM; in
more specialised settings this is augmented with detection of
DENV RNA using home made RT-PCR or rarely, virus isolation
[4,5]. Whilst generally robust, a limitation of IgM-based diagnostic
approaches is poor sensitivity in the first few days of illness and in
some settings, serological cross-reactivity with other Flaviviruses
[4,5]. Recently, the diagnostic accuracy of commercial diagnostic
assays that detect the DENV NS1 protein in plasma/serum
samples have been described [6–13]. NS1 is a 55kDa glycoprotein
secreted by DENV infected cells ‘‘in vitro’’ and ‘‘in vivo’’. Whilst
the role of NS1 in DENV biology is not well understood, high
plasma NS1 concentrations early in illness have been associated
with more severe disease [14,15]. The targeting of NS1 in
diagnostic assays potentially offers the opportunity for an early,
specific diagnosis of DENV infection since it can be detected prior
to the appearance of measurable DENV-reactive IgM [8]. Whilst
NS1 is a promising diagnostic target, the assessment of currently
available NS1 assays across a breadth of patient populations, viral
serotypes and lineages is important in evaluating where and when
these assays [16] may fit into the laboratory diagnosis of dengue.
At the end of 2006, the Dengue Scientific Working Group under
the leadership of the World Health Organization Special Pro-
gramme for Research and Training in Tropical Diseases (WHO/
TDR) established priorities for dengue research aimed at improving
dengue treatment, prevention and control. The evaluation of new
diagnostics were included among these priorities [17,18]. To this
end, the purpose ofthe current studywastoassessthesensitivity and
specificity of two commercial NS1 assays in six countries.
Materials and Methods
The DENCO study
The DENCO project was a multi-centre prospective observa-
tional study of dengue in Southeast Asia (Malaysia, Thailand, The
Philippines and Vietnam) and the Americas (Nicaragua and
Venezuela). The study sites at which patients were enrolled were:
Department of Paediatrics, Faculty of Medicine, University of
Malaya, Kuala Lumpur, Malaysia; Queen Sirikit National Institute
of Child Health, Bangkok, Thailand; San Lazaro Hospital, Manila,
The Philippines; Hospital for Tropical Disease, Ho Chi Minh City,
Viet Nam, Children’s Hospital #1, Ho Chi Minh City, Viet Nam;
Children’s Hospital #2, Ho Chi Minh City, Viet Nam; Children’s
Hospital Manuel Jesus de Rivera, Managua, Nicaragua; Research
Centre Jose W. Torrealba, University des Andes, Trujillo and
Hospital Central, Maracay, Venezuela.
Author Summary
Dengue is the most important mosquito-borne viral
disease of humans and an enormous public health burden
in affected countries. Early, sensitive and specific diagnosis
of dengue is needed for appropriate patient management
as well as for early epidemic detection. Commercially
available assays that detect the dengue virus protein NS1
in the plasma/serum of patients offer the possibility of
early and rapid diagnosis. Here we evaluated two
commercially available ELISA kits for NS1 detection (Pan-
E Dengue Early ELISA and the Platelia
TM Dengue NS1 Ag).
Results were compared against a reference diagnosis in
1385 patients in 6 countries in Asia and the Americas.
Collectively, this multi-country study suggests that the
best performing NS1 assay (Platelia) had moderate
sensitivity (median 64%, range 34–76%) and high specific-
ity (100%) for the diagnosis of dengue. The combination of
NS1 and IgM detection in samples collected in the first few
days of fever increased the overall dengue diagnostic
sensitivity.
Figure 1. Flow chart summarising multi-country enrolment of dengue patients and basis for the final dataset.
doi:10.1371/journal.pntd.0000811.g001
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Following written informed consent by the study participant, or a
parent/guardian in the case of children, patients above 6 months of
age with clinically suspected dengue and fever for less than 7 days
were enrolled in the study. At 5 centres out-patients were recruited
as well as in-patients. Patients were followed daily by trained study
physicians using standardised case report forms (CRFs) describing
clinical, laboratory, diagnostic and management information in
detail. Ethical approval was obtained from the Ethics Review
Committee of WHO and each institution involved. All patients in
these studies were assessed daily by a study physician and had serial
haematocrit and platelet estimations performed, as well as
appropriate sampling for diagnostic serology and virology. Two
plasma or sera samples were collected from each patient, one at day
of the enrolment and the second 7–14 days after fever onset.
Denguediagnosiswasconfirmed byeitherof the followingmethods:
virus isolation in Aedes albopictus cell line (C6/36), by RT/PCR
detection as previously described and IgM (MAC-ELISA), IgG
(GAC-ELISA or Inhibition ELISA Method, EIM) and total
antibody seroconversion (by Hemagglutination Inhibition assay)
following the standard procedures at each study site [19–30]. The
Hemagglutination Inhibition assay was standardized following
WHO criteria and WHOrecommended cut-off values were utilized
[29]. As previously described, RT/PCR methods used here have
sensitivity figures from 90 to 100% [20–23]. Other investigations
and clinical management were at the discretion of the attending
physicians. After discharge each patient was classified using the
formerWHO criteria for DF,DHF and DSS [30]. From November
Table 1. List of laboratories performing diagnostic testing for the patients enrolled in the DENCO study.
Location / Country Hospital Laboratory
Bangkok / Thailand Queen Sirikit National Institute
of Child Health
AFRIMS, Bangkok* – all tests
Manila / Philippines San Lazaro Hospital AFRIMS certified laboratory at San Lazaro Hospital* for serology
PCR performed at Department of Virology, Nagasaki University, Nagasaki, Japan;
serotyping done at San Lazaro Hospital, Manila, biomolecular laboratory (SACCL)
Ho Chi Minh City / Vietnam Children’s Hospital No. 1 Oxford University Clinical Research Unit, HCMC** – all tests
Children’s Hospital No. 2
Hospital for Tropical Diseases
Kuala Lumpur / Malaysia University of Malaya Medical
Centre, University of Malaya
Department of Medical Microbiology, Faculty of Medicine, University Malaya** - all
tests
Managua / Nicaragua Hospital Infantil Manuel de Jesus
Rivera La Mascota
Centro Nacional de Diagno ´stico y Referencia, Ministry of Health, Managua
– all tests
IgM, IgG and NS1 repeated at IPK Cuba**
Maracay & Trujillo/ Venezuela Hospital Central de Maracay
Hospital de Trujillo
Trujillo Hospital Laboratory – all tests
IgM, IgG, viral isolation repeated and NS1 done at IPK Cuba**
AFRIMS - Armed Forces Research Institute of Medical Sciences, IPK - Instituto de Medicina Tropical ‘‘Pedro Kouri’’.
*AFRIMS laboratory network in Asia.
**Member of the Tropical Disease Research –Pediatric Dengue Vaccine Initiative network of proficiency tested laboratories for dengue diagnostic evaluation.
doi:10.1371/journal.pntd.0000811.t001
Table 2. Laboratory criteria employed at country level for dengue laboratory classification as confirmed dengue case.*
Country Confirmed dengue case (one of the following)**
Patients without evidence of recent acute dengue
(all countries)
All countries RT-PCR positive or virus isolation positive Having paired plasma or serum specimens (collected $3
days apart) with the last sample collected $7 days after
illness onset and RT-PCR negative and virus culture
negative (at least one of the two being done on the
acute sample), and serologically negative in locally used
IgM and IgG assays
Thailand, The Philippines (according
to AFRIMS protocol)
IgM.=40 units (acute or convalescent sample or both)
and IgG titer increase to above 100 units (paired samples)
Twofold IgG titer increase (paired samples) with a
titer .=100 units in the convalescent sample
Malaysia, Nicaragua, Venezuela, Vietnam IgM seroconversion (paired samples)
IgG seroconversion (paired samples) or fourfold or
greater increase in titer (paired samples)
*For each test validated local protocols were used at each site. Serology results are based on IgM and IgG Capture ELISA of acute and convalescent specimens except
where indicated.
**Four laboratories employed the RT/PCR protocol described by Lanciotti, et al., 1992 [20], one employed the protocols by Kong et al., 2006, J Virol Methods and Yong
et al., 2007 Singaporean Med J [22,23],and the other the protocol by Laue et al., . J Clin Microbiol 1999 [21]. All laboratories employed MAC-ELISA. One laboratory
employed Inhibition ELISA Method for IgG study while other four used GAC-ELISA. HI: hemagglutination inhibition assay was done in one laboratory (WHO
recommendations were followed) [30].
doi:10.1371/journal.pntd.0000811.t002
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serum) samples from children and adults enrolled in these studies.
Characteristics of the study population
Between August 2006 and May 2007 a total of 2259 patients
were recruited to the DENCO study at the 11 participating
hospitals. NS1 detection was attempted using at least one of the
two NS1 tests in 1821 patients. From amongst the 1821 patients,
there were 1385 with laboratory-confirmed dengue and 45 with no
laboratory evidence of acute or recent dengue. A further 391 had
either indeterminate laboratory results or suggestive serology;
results from these cases were not included in the analysis. The
flow-chart in Figure 1 summarises the numbers and geography of
enrolment and the classification of patients according to the results
of reference diagnostic tests including demographic information.
Laboratory investigations
Serological and virological dengue diagnostics were performed
in each participating country according to local protocols, with
support provided by WHO designated laboratories as necessary
(for participating laboratories see Table 1) [19–30]. The definitions
employed at each site for ‘‘confirmed dengue case’’ are described
in Table 2. For NS1 sensitivity analysis, patients with laboratory
confirmation of dengue by serological or virological means were
the reference population. For an assessment of NS1 specificity,
patients in whom there was no evidence of acute or recent dengue
(defined as serologically and virologically negative and in whom
there were a minimum of 2 plasma or serum samples tested with
the second collected $7 days after fever onset and .2 days after
the first sample) were studied. As an additional assessment of
specificity, two sera panels (one prepared at the Institute of
Tropical Medicine ‘‘Pedro Kouri’’ in Cuba and the other at the
Mahidol University, Bangkok, Thailand) from healthy individuals
and from non-dengue patients were employed.
NS1 detection kits
Pan-E Dengue Early ELISA from Panbio (Brisbane, Australia),
(Kit Pan-E) and Platelia Dengue NS1 AG from Bio-Rad (Marnes-
la-Coquette, France), (kit Platelia) were evaluated. Both kits are
based on a sandwich format microplate enzyme immunoassay for
the detection of DENV NS1 employing a peroxidase-labelled
murine monoclonal antibodies as probes. Samples were tested for
NS1 detection following the manufacturer’s recommendations.
Sera were classified as NS1 positive, negative and equivocal
according to the manufacturer’s instructions. For the purposes of
analysis, equivocal samples were excluded from the analysis.
Data management and analysis
Data were double-entered and checked at two established data-
entry facilities in Guatemala (Center for Health Studies,
Universidad del Valle de Guatemala) and Thailand (WHO/
TDR Clinical Data Management Collaborating Center, Faculty of
Allied Health Sciences, Thammasat University, Thailand) and the
two datasets were subsequently merged. Data analysis was
performed at the Section of Clinical Tropical Medicine at the
University of Heidelberg, Germany, using STATA versions 9.2
and 10, (STATA corporation, College Park, Texas).
Results
Overall sensitivity of NS1 tests versus reference diagnosis
of confirmed dengue
The diagnostic sensitivity of kits Pan-E and Platelia assays was
evaluated in 854 and 1284 serum samples respectively (Figure 1)
from patients with a laboratory confirmed dengue diagnosis. Kit
Pan-E it could not be performed in all available samples for
logistical reasons relating to assay availability at some sites. The
sensitivity of the kit Pan-E ranged from 24% in The Philippines to
72% in Vietnam (overall sensitivity rate of 52%). The sensitivity of
the kit Platelia ranged from 34% in Nicaragua to 76% in Thailand
(overall sensitivity rate of 66%) (Figure 2A).
NS1 sensitivity in relation to RT/PCR results
Compared to RT/PCR results, sensitivity of kit Pan-E ranged
from 29–79% (overall sensitivity rate of 67%; 95% CI 63–71%)
and the sensitivity of kit Platelia from 36–88% (overall sensitivity
rate of 77%; 95% CI 74–79%) (Figure 2B).
Sensitivity of NS1 tests by day of illness
The sensitivity of both kits Pan-E and Platelia was influenced by
the patient’s duration of illness prior to test sample collection.. In
Asian patients, kits Pan-E and Platelia were more sensitive in test
samples collected early in the disease phase than at later time points
(Figure 3A). The analysis was limited to days with more than 40
observations total which is why for Latin America only a narrow
range of days can be shown (Figure 3B) and due to small sample size
and largeconfidenceintervalsno trend is visible.A highersensitivity
ofbothNS1detectionassayswereobservedinAsianpatientsthanin
Latin-American patients at the first four days of illness (Figure 3B).
NS1 sensitivity in relation to viral serotype
The sensitivity of each NS1 assay was considered in the context
of the infecting serotype. Table 3 shows the sensitivity of kit Pan-E
and Platelia assays according to DENV serotype as determined by
RT-PCR or virus isolation. In our mainly hospital-based patient
samples from 2006/2007 DENV-1 was most prevalent in Asia and
DENV-2 most prevalent in Latin America (Table 4). For each of
the four DENV serotypes kit Platelia had a greater sensitivity
except for DENV-2, where the sensitivity was the same in both
kits. In kit Platelia, sensitivity for DENV-2 was statistically
significantly lower than for the other three serotypes pooled
(DENV-2: 63%; 95% CI 57–69% versus 84%; 95% CI 82–88%
for DENV-1, 3 and 4). The greater prevalence of DENV-2 in
Latin American patients compared with Asian patients may help
explain the lower sensitivity of both kit Pan-E and Platelia assays in
Latin America (Figure 3B).
NS1 sensitivity in relation to IgM status
Detection of DENV-reactive IgM by MAC ELISA is the most
commonly used approach to making a presumptive diagnosis of
acute or recent dengue in endemic countries. Table 5 summarises
NS1 sensitivity (kit Platelia assay only) in the context of IgM status
and day of illness in confirmed dengue patients. The average
sensitivity of NS1 testing in the first 7 days of sample collection was
65% (95%CI 62–69%) in acute samples where the IgM result was
negative and 66% (95%CI 62–70%) when the acute test sample
Figure 2. Sensitivity of kits Pan-E and Platelia. Shown are the sensitivities (695% CI) of kits Pan-E and Platelia assays from six Asian and Latin-
American countries in 1385 patients with a laboratory confirmed diagnosis of dengue (A) and sensitivities in the subgroup of 933 patients confirmed
by PCR or viral isolation (B).
doi:10.1371/journal.pntd.0000811.g002
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only samples collected in the first four days of illness were
considered. Taking an algorithmic approach, when either the NS1
test or the IgM test on the acute sample was positive, the sensitivity
for a presumptive (IgM) or definitive (NS1) diagnosis versus the
reference result was 74% (95%CI 69–78) in samples collected at
days 5 to 7. These figure increased to 82% (95%CI 79–84) in
samples collected in the first four days of fever. These results
suggested a combination of either IgM testing or NS1 testing (with
kit Platelia) was sufficient to allow a presumptive (IgM) or
definitive (NS1) diagnosis on an average of 82% of dengue cases
enrolled in this study when acute early samples are tested. A
similar analysis was performed with data obtained in the
evaluation of kit Pan-E. Sensitivity figures of 66% (95%CI 60–
72) in samples collected at days 5 to 7 and 71% in samples
collected in the first four days of fever (95%CI 67–75) were
obtained (Table S1).
NS1 sensitivity according disease severity
The sensitivity of each NS1 assay was considered in the context
of disease severity and geographical region (Table 6). Cases were
classified according the former WHO criteria for DF and DHF/
DSS [27]. Sensitivity of kit Pan-E ranged from 29% (95%CI 12–
46) in DF to 60% (95%CI 39–82) in DHF cases from Latin-
American countries and from 50% (95%CI 43–57) in DF to 62%
(95%CI 57–67) in DHF/DSS cases from Asia (overall sensitivity
47% in DF and 62% in DHF/DSS cases). The sensitivity of kit
Platelia ranged from 41% (95%CI 28–55) in DF and 68% (95%CI
47–89) in DHF/DSS cases from Latin-American countries and
70% (95%CI 66–75) in DF and 68% (95%CI 64–72) in DHF/
DSS cases from Asia (overall sensitivity of 68% for both DF and
DHF/DSS total cases). Kit Pan-E showed higher figures of NS1
positive tests in severe cases, which are borderline statistically
significant for Asia. Kit Platelia with overall higher sensitivity
figures did not show a statistically significant association with
disease severity.
Overall specificity of NS1 tests versus reference diagnosis
The diagnostic specificity of kits Pan-E and Platelia assays was
evaluated in 36 and 45 samples respectively from patients with no
virological or serological laboratory evidence of acute or recent
dengue. Both kits were negative in all these samples, which
translates into a specificity of 100%.
NS1 specificity in healthy blood donors and patients with
other confirmed diagnoses
Since the number of patients with no evidence of acute or recent
dengue was relatively small (n=45) in this study, efforts were made
to assess the specificity of dengue NS1 assays in patients with other
confirmed infectious diseases whose transmission geographically
overlaps with dengue, in healthy blood donors, and in blood
donors with a serological history of DENV exposure. For the
specificity analysis, a total of 304 sera were tested at two study sites
(Cuba and Thailand). The specificity of kit Platelia was 100% in
both sites whilst the kit Pan-E was 89% (Table 7). The lower
specificity of kit Pan-E was in part due to false positive results in
patients with Japanese encephalitis, Yellow Fever and acute
Influenza.
Discussion
Dengue is increasing in incidence globally and therefore
accurate and efficient diagnostic tests are more important than
ever for clinical care, surveillance support, pathogenesis studies
and vaccine research. Diagnosis is also important for case
confirmation, to differentiate dengue from other diseases such as
leptospirosis, rubella, and other flavivirus infections, and for the
clinical management and evaluation of patients with severe disease
[16,31]. The multicentre study described here assessed the
diagnostic accuracy of two commercially available NS1 diagnostic
tests. Two main findings were observed here: a) NS1 detection was
overall only modestly sensitive for dengue diagnosis, with
sensitivity highest in patients who presented early in their illness
and b) a combined NS1 and IgM detection increased the overall
sensitivity of dengue diagnostic.
Figure 3. NS1 sensitivity by day of illness. (A) Shown is the sensitivity (695% CI) of kits Pan-E and Platelia by day of illness in four Asian
countries (N=728 -kit Pan-E; N=1152 -kit Platelia) amongst patients with a laboratory confirmed diagnosis of dengue where the acute sera were
collected between day 2 and day 6 of illness. (B) Shown is the sensitivity (695% CI) of kits Pan-E and Platelia in the first four days of illness in two
Latin American countries (N=93 -kit Pan-E; N=90 -kit Platelia) amongst patients with a laboratory confirmed diagnosis of dengue where the acute
sera were collected between day 2 and day 4 of illness. Data is presented for those days of illness with .=40 observations respectively.
doi:10.1371/journal.pntd.0000811.g003
Table 3. NS1-sensitivity in the context of DENV serotype.
Serotype Kit Pan-E Kit Platelia
*N=506
% Sensitivity
(95%CI) N=862
% Sensitivity
(95%CI)
DENV-1 223 79 (74–84) 415 87 (83–90)
DENV-2 169 62 (54–69) 257 63 (57–69)
DENV-3 87 60 (49–70) 142 82 (76–88)
DENV-4 27 52 (32–72) 48 79 (67–91)
*Number of DENV-positive samples by virus isolation or RT-PCR and serotype
determined.
doi:10.1371/journal.pntd.0000811.t003
Table 4. Geographical and serotype stratification of the study
population.
Country DENV-1
a DENV-2 DENV-3 DENV-4 Total
Latin America
Nicaragua 6% (2) 94% (32) 0 0 34
Venezuela 35% (19) 16% (9) 36% (20) 13% (7) 55
Mean 24% (21) 46% (41) 22% (20) 8% (7) 89
Asia
Malaysia 62% (48) 9% (7) 17% (13) 13% (10) 78
Thailand 56% (86) 10% (15) 17% (26) 17% (26) 153
Philippines 0 10% (3) 87% (26) 3% (1) 30
Vietnam 47% (268) 35% (198) 10% (59) 1% (5) 568
Mean 48% (411) 27% (227) 15% (126) 5% (45) 829
aPercentages and absolute numbers (in brackets) of identified DENV serotypes
by country.
doi:10.1371/journal.pntd.0000811.t004
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validity, role and accessibility of available and new diagnostics of
importance to reducing disease severity and case fatality [32].
Recognizing the importance of early diagnosis and taking
advantage of the platform of the multicentre DENCO project,
two commercial available NS1 detection ELISA kits (Pan-E Early
Dengue, Panbio Ltd and Platelia
TM Dengue NS1 Ag, Bio-Rad ),
named here as kits Pan-E and Platelia, were evaluated in terms of
sensitivity and specificity. Overall and within country sensitivity
figures were higher for kit Platelia than kit Pan-E. With the
exception of Nicaragua and The Philippines, sensitivity figures of
kit Platelia varied from 64% to 76% while the sensitivity of kit Pan-
E varied from 36% to 72%. Depending on the diagnostic method
used for comparison, different figures of sensitivity of NS1
detection have been reported by others [12,33,34]. Kumarasamy
et al., obtained an overall sensitivity of 93% using Platelia
TMDen-
gue NS1 Ag oscillating from 68% (in samples where the virus was
isolated) to 90% in paired sera serologically confirmed as dengue
[11,35].
In the present study, relatively higher levels of sensitivity were
observed in samples collected in the first four days of fever when
samples from Asian patients were studied (interpretation limited
for Latin America because of small sample size per day of illness)..
Sensitivity was also higher in Asian patients compared with
patients from Nicaragua and Venezuela. The small number of
samples from Nicaraguan and Venezuelan patients (including a
lower proportion of DHF/DSS cases) as well as the serotypes
circulating could partially explain these observations (a high
proportion of serotype 2 was found in Nicaraguan samples). The
influence of duration of illness at the time of sample collection has
been highlighted by others [6,8,10]. Figures of 93–100% sensitivity
were obtained in samples collected at days 3 to 5 of fever [8] while
others have reported figures higher than 85% in samples from day
1 to 3 in the Platelia assay [6,11].
NS1 protein has been detected concomitant with viremia and
coincident with the febrile stage [8].
In the present study, the highest sensitivity was obtained in RT-
PCR positive samples. Sensitivity of kit Platelia in RT-PCR
positive samples was 71% to 88% in Asian countries and 66% in
Venezuela, but much lower in Nicaraguan samples (36%).
Samples from this country were retested in a different laboratory
by both NS1 detection kits but similar sensitivity results were
observed (data not showed). The basis for low sensitivity in
Nicaraguan samples remains unclear and will require further
studies – but may partly be explained by the high proportion of
serotype 2 in Nicaragua, which in both assays was associated with
lower sensitivity. Indeed, as 94% (N=32) of the serotypes
recovered from Nicaragua were serotype 2, we cannot determine
an estimate of sensitivity for the remaining 6% (N=2).
Sensitivity varied by infecting serotype for each kit. The
sensitivity of kit Pan-E was highest for DENV-1 infection (77%)
and significantly lower for DENV-2 (60%), DENV-3 (57%) and
DENV-4 (52%). The sensitivity of kit Platelia was also highest for
DENV-1 infection (83%) and lowest for DENV-2 (60%).
Consistent with DENV-1 infection being associated with high
levels of NS1 detection, Xu et al., 2006, reported a sensitivity of
82% in an ‘‘in house’’ ELISA for the detection of NS1 protein of
DENV-1 [36]. Similar results for the same serotype were reported
by Alcon et al., 2002 [8]. The basis for different sensitivities for
different serotypes requires further investigation. Potentially, this
reflects different levels of avidity of the test mAbs for the relevant
epitope(s) in NS1 from different serotypes, and potentially,
Table 5. NS1 detection (kit Platelia assay only) in relation to IgM status and day of illness.*
Day of illness
Total no. of
test samples
IgM positive
N=
% NS1 positive
in IgM positive
test samples [41]
IgM negative
N=
% NS1 positive in
IgM-negative test
samples [41]
% NS1 positive in
total no. of test
samples
% of test samples
with a positive test
(IgM or NS1) [41]**
Day 1 22 0 0 (0) 22 64 (14) 64(14) 64 (14)
Day 2 139 27 56 (15) 112 77 (86) 73 (101) 81 (113)
Day 3 372 123 78 (96) 249 71 (178) 74 (274) 81 (301)
Day 4 384 198 74 (146) 186 66 (122) 70 (268) 83 (320)
Subtotal ,5 days 917 348*** 74 (257) 569 70 (400) 72 (657) 82 (748)
Day 5 256 125 54 (67) 131 52 (68) 53 (135) 75 (193)
Day 6 94 42 40 (17) 52 44 (23) 43 (40) 69 (65)
Day 7 6 4 75 (3) 2 0 50 (3) 67 (4)
Subtotal 5–7 days 356 171 51 (87) 185 49 (91) 50 (178) 74 (262)
Total 1273 519*** 66 (344) 754 65 (491) 66 (835) 79 (1010)
*Samples from 1273 patients with a confirmed dengue diagnosis between day of illness 1 to 7.
**Percentage of positives IgM samples plus positive NS1 samples of the IgM negative samples in the total tested samples.
***Percentages of IgM positive in total samples collected in the first four days (38%), days 5–7 (48%) and total (41%).
doi:10.1371/journal.pntd.0000811.t005
Table 6. Sensitivity of Kit Platelia and Pan-E by geographic
region and disease severity.*
LAC** SEA** Total
DF*** DHF/DSS DF DHF/DSS DF DHF/DSS
Platelia 32/13
41%
(28–55)
22/15
68%
(47–89)
369/260
70%
(66–75)
628/427
68%
(64–72)
401/273
68%
(63–73)
650/442
68%
(64–72)
Pan-E 31/9
29%
(12–46)
23/14
60%
(39–82)
228/114
50%
(43–57)
396/245
62%
(57–67)
259/123
47%
(41–54)
419/259
62%
(57–66)
*As indicated by the former WHO classification into DF and DHF/DSS for
patients with NS1 test result and clinical classification available (N=1051 for
Platelia and 678 for Pan-E).
**LAC (Latin-American countries), SEA (Asian countries).
***N/positive NS1; % ; (95% CI).
doi:10.1371/journal.pntd.0000811.t006
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potentially be related to the different sensitivities of the reference
RT/PCR methods employed for dengue diagnosis. Alternatively,
this might reflect different overall magnitudes of virus burden in
patients with different serotypes. A relationship between NS1
detection and viraemia levels has been established previously
[12,15]. Since high early viraemia levels have also been linked to
increased disease severity, it is plausible that NS1 tests are more
sensitive in the first few days of illness in patients at risk of
developing severe complications in their illness compared to
patients with a more benign disease evolution. However, in our
study, no association between NS1 detection and disease severity
(indicated by classification of DF or DHF/DSS) was observed.
Furthermore a regression analysis on NS1 positivity for DHF/DSS
vs. DF (or severe vs. mild) and adjusted for serotype and for
country was done and there was no effect seen (data not shown).
The specificity of NS1 tests could not accurately be estimated in
the DENCO patient population as only a small number of cases
had no serological or virological evidence of acute or recent
dengue. Nonetheless, in patients who met our criteria for ‘‘not
dengue’’, the specificity of both NS1 test kits was very high (100%).
To provide further insights into specificity, two sera panels from
patients with other confirmed diagnosis and healthy individuals
were tested. Kit Platelia showed the higher specificity (100%).
Similar specificity values has been previously reported by others
[10,11,15,37]. The inclusion into the evaluating panel of samples
from patients with acute Yellow fever and Japanese encephalitis
virus infections suggest that no cross reaction among flaviviruses is
observed with kit Platelia, however a larger number of samples
collected from acute flavivirus infected patients need to be studied.
The dengue serotype, duration of illness prior to sample collection,
andthepresenceofimmunocomplexes(NS1-IgG)inpreviousdengue
immune individuals could explain the low sensitivity observed in the
Nicaraguan and The Philippines samples [38]. In the case of
Nicaragua, DENV-2 was present in the 94% of the samples where
the virus was identified by virus isolation and RT/PCR suggesting
that this was the predominant serotype. The generally poor sensitivity
for DENV-2 (60%) observed for both assays suggests this partially
explains the low sensitivity in Nicaraguan samples [12]. In The
Philippines, a conjunction of factors such as to the duration of illness
prior to sampling and the high level of individuals with a secondary
infection could partially explain the low sensitivity since high
sensitivity was observed in RT-PCR positive samples (83%).
One of the limitations of our study is that it is heavily biased
towards Asian patients and viruses, with 93% of the total samples
coming from this region. The strengths of our study were that it
was multicentre, prospective and encompassed a broad range of
DENV serotypes and clinical presentations.
It is important to mention that no proficiency panel study on positive
or negative samples was performed prior to evaluating the tested
samples allowing us to have more comparable reference methods
among participant laboratories. However protocols employed at each
site, have been extensively evaluated previously [19–30]. In addition,
the laboratories participants (including some WHO collaborating
centres) are the reference centres for dengue diagnosis and laboratory
surveillance in their respective countries and have participated in
previous regional and international proficiency testing ([39,40]
This study confirms and extends the findings of others in
relation to the use of NS1 detections assays for the early diagnosis
of dengue [6–12]. Although we could not study NS1 sensitivity
and specificity in primary and secondary cases, in a small subset of
samples classified as primary or secondary cases, a higher
percentage of diagnose (90% over 80.6%) was obtained in the
former (Vazquez S, manuscript in preparation).
In summary, we found the kit Platelia to be more sensitive and
specific than kit Pan-E, with the sensitivity of both assays highest in
the first few days of illness. Furthermore, we found that NS1
testing combined with IgM testing on the same test sample could
yield a presumptive (IgM) or definitive (NS1) diagnose in as many
as 82% of confirmed dengue cases using samples collected in the
first four days of fever. As IgM detection is widely used for making
a presumptive dengue diagnosis and in epidemiological surveil-
lance, the use of a combined diagnostic algorithm including NS1
and IgM detection in samples collected in the first days of fever
could provide clinically useful information to assist patient triage,
management and outbreak response.
Supporting Information
Checklist S1 STARD checklist.
Found at: doi:10.1371/journal.pntd.0000811.s001 (0.13 MB
DOC)
Table S1 NS1 detection (kit Pan-E assay only) in relation to IgM
status and day of illness.
Found at: doi:10.1371/journal.pntd.0000811.s002 (0.05 MB
DOC)
Table 7. NS1 results as determined by Kit Pan-E and Platelia assays in control sera panels.
Panel 1 (Cuba) Panel 2 (Thailand)
NS1 negative results NS1 negative results
Sera N Kit Pan-E Kit Platelia Sera N Kit Pan-E Kit Platelia
Healthy blood donors 80 76 80 Acute Malaria sera 39 38 39
Cases with rash illness no dengue 10 8 10 Acute Leptospirosis sera 10 8 10
Acute Influenza sera 20 13 20 Acute Japanese Encephalitis sera 34 24 34
Acute RSV* sera 20 17 20 Acute Yellow Fever sera 15 12 15
Acute Hepatitis A sera 20 20 20 Dengue mono- or polyvalent immune
sera (past infection)
27 27 27
-- - - Flavivirus non-immune sera 29 29 29
Total 150 134 150 Total 154 138 154
Specificity 90% 100% 90% 100%
*RSV (Respiratory Syncitial Virus).
doi:10.1371/journal.pntd.0000811.t007
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